Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia - PubMed (original) (raw)
Clinical Trial
. 2010 Aug 20;28(24):3880-9.
doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26.
Susan O'Brien, Stefan Faderl, Guillermo Garcia-Manero, Alessandra Ferrajoli, William Wierda, Farhad Ravandi, Srdan Verstovsek, Jeffrey L Jorgensen, Carlos Bueso-Ramos, Michael Andreeff, Sherry Pierce, Rebecca Garris, Michael J Keating, Jorge Cortes, Hagop M Kantarjian
Affiliations
- PMID: 20660823
- PMCID: PMC2940403
- DOI: 10.1200/JCO.2009.26.9456
Clinical Trial
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
Deborah A Thomas et al. J Clin Oncol. 2010.
Abstract
Purpose: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone). Other modifications (irrespective of CD20 expression) included early anthracycline intensification, alterations in number of risk-adapted intrathecal chemotherapy treatments for CNS prophylaxis, additional early and late intensifications, and extension of maintenance phase chemotherapy by 6 months.
Patients and methods: Two hundred eighty-two adolescents and adults with de novo Philadelphia chromosome (Ph)-negative precursor B-lineage ALL were treated with standard or modified hyper-CVAD regimens. The latter incorporated standard-dose rituximab if CD20 expression > or = 20%.
Results: The complete remission (CR) rate was 95% with 3-year rates of CR duration (CRD) and survival (OS) of 60% and 50%, respectively. In the younger (age < 60 years) CD20-positive subset, rates of CRD and OS were superior with the modified hyper-CVAD and rituximab regimens compared with standard hyper-CVAD (70% v 38%; P < .001% and 75% v 47%, P = .003). In contrast, rates of CRD and OS for CD20-negative counterparts treated with modified versus standard hyper-CVAD regimens were similar (72% v 68%, P = not significant [NS] and 64% v 65%, P = NS, respectively). Older patients with CD20-positive ALL did not benefit from rituximab-based chemoimmunotherapy (rates of CRD 45% v 50%, P = NS and OS 28% v 32%, P = NS, respectively), related in part to deaths in CR.
Conclusion: The incorporation of rituximab into the hyper-CVAD regimen appears to improve outcome for younger patients with CD20-positive Ph-negative precursor B-lineage ALL.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
Outcomes by therapy for younger patients (age younger than 60 years) with Philadelphia chromosome–negative precursor B-lineage acute lymphoblastic leukemia. In the CD20-positive subset, (A) complete remission (CR) duration and (B) survival by inclusion or exclusion of rituximab therapy, and (C) survival by hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone) regimen (standard, modified hyper-CVAD 1 with rituximab inclusive of anthracycline intensification, or modified hyper-CVAD 2 with rituximab eliminating anthracycline intensification) are depicted. (D) Survival by regimen (without rituximab) for the CD20-negative group is also depicted.
Fig 2.
Outcomes by therapy for older patients (age 60 years or older) with Philadelphia chromosome–negative precursor B-lineage acute lymphoblastic leukemia. (A) In the CD20-negative subset, survival by regimen is depicted. (B) In the CD20 positive subset, complete remission (CR) duration (CRD) and survival by rituximab therapy is depicted. OS, overall survival.
Similar articles
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Thomas DA, et al. Blood. 2009 Jun 18;113(25):6330-7. doi: 10.1182/blood-2008-04-151860. Epub 2008 Aug 14. Blood. 2009. PMID: 18703706 Free PMC article. - Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Thomas D, et al. Cancer. 2010 Oct 1;116(19):4580-9. doi: 10.1002/cncr.25319. Cancer. 2010. PMID: 20572037 Free PMC article. - Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2020 Jul;7(7):e523-e533. doi: 10.1016/S2352-3026(20)30144-7. Lancet Haematol. 2020. PMID: 32589978 Clinical Trial. - The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Garcia-Manero G, Kantarjian HM. Garcia-Manero G, et al. Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi. doi: 10.1016/s0889-8588(05)70192-1. Hematol Oncol Clin North Am. 2000. PMID: 11147229 Review. - Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005. Drugs. 2003. PMID: 12662126 Review.
Cited by
- Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).
Khawaji ZY, Khawaji NY, Alahmadi MA, Elmoneim AA. Khawaji ZY, et al. Curr Treat Options Oncol. 2024 Sep;25(9):1163-1183. doi: 10.1007/s11864-024-01237-w. Epub 2024 Aug 5. Curr Treat Options Oncol. 2024. PMID: 39102166 Review. - Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts.
Holzmayer SJ, Kauer J, Mauermann J, Roider T, Märklin M. Holzmayer SJ, et al. Cancers (Basel). 2024 Mar 26;16(7):1288. doi: 10.3390/cancers16071288. Cancers (Basel). 2024. PMID: 38610966 Free PMC article. - Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma.
Saburi M, Sakata M, Maruyama R, Kodama Y, Uraisami K, Takata H, Miyazaki Y, Kawano K, Kodama Y, Ohtsuka E. Saburi M, et al. Leuk Res Rep. 2024 Feb 3;21:100413. doi: 10.1016/j.lrr.2024.100413. eCollection 2024. Leuk Res Rep. 2024. PMID: 38348414 Free PMC article. - Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy.
Yoon JH, Lee S. Yoon JH, et al. Korean J Intern Med. 2024 Jan;39(1):34-56. doi: 10.3904/kjim.2023.407. Epub 2024 Jan 1. Korean J Intern Med. 2024. PMID: 38225824 Free PMC article. Review. - Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study.
Tozawa N, Yamashita T, Nara M, Fujioka Y, Ikeda S, Kobayashi T, Kobayashi I, Kitadate A, Kameoka Y, Takahashi N. Tozawa N, et al. Cureus. 2023 Dec 12;15(12):e50416. doi: 10.7759/cureus.50416. eCollection 2023 Dec. Cureus. 2023. PMID: 38222242 Free PMC article.
References
- Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561–1570. - PubMed
- Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007;67:1270–1281. - PubMed
- Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B- precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood. 1997;89:3960–3966. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous